Arcturus Therapeutics
3210 Merryfield Row
San Diego
California
92121
United States
Tel: 858-242-1526
Website: http://www.arcturusrx.com/
Email: info@ArcturusRx.com
60 articles with Arcturus Therapeutics
-
Arcturus Therapeutics to Attend Upcoming Investor Conferences
2/6/2023
Arcturus Therapeutics Holdings Inc. today announced that the Company will participate in the following investor conferences.
-
Arcturus Therapeutics to Attend the Following Investor Conferences
9/27/2022
Arcturus Therapeutics Holdings Inc. today announced that the Company will participate in the following investor conferences.
-
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
8/18/2022
Arcturus Therapeutics Holdings Inc. today announced updated data from its ongoing ARCT-154 booster clinical trial.
-
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
5/5/2022
Arcturus Therapeutics Holdings Inc. today provided updated data from its Phase 1/2 booster clinical trial showing durability of antibody response with ARCT-154 for at least three months after low-dose (5 mcg) booster.
-
Arcturus Therapeutics announced positive Phase III trial results for its mRNA vaccine candidate, ARCT-154, intended to prevent COVID-19 caused by the SARS-CoV-2 virus.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
10/12/2021
Arcturus Therapeutics Holdings Inc. today announced that the Vietnam Ministry of Health has approved initiation of the Phase 3b part of the placebo-controlled, observer-blind Phase 1/2/3 clinical trial of ARCT-154 self-replicating RNA vaccine targeting the SARS-CoV-2 delta variant and other variants of concern.
-
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
9/22/2021
Arcturus Therapeutics Holdings Inc. today announced that Arcturus’ President & CEO, Joseph Payne, met with the President of Vietnam, Nguyen Xuan Phuc, and the CEO of the Vingroup, Nguyen Viet Quang, in New York City to discuss the ongoing collaboration recently announced between Arcturus and Vingroup related to the manufacturing supply of COVID-19 vaccines
-
Arcturus CEO: Investigational COVID-19 Vaccine Could Play Notable Role in Managing the Pandemic
9/23/2020
Arcturus CEO Joseph Payne told BioSpace in an interview that his company’s vaccine candidate is a low-dose, single-shot treatment that generated not only neutralizing antibody titers, but also CD8+ T-cell induction in preclinical studies. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
-
BioSpace Movers & Shakers, Aug. 7
8/7/2020
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers and Shakers. -
Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020
8/4/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2020 after the market close on August 10 and will also provide a corporate overview and financi
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 22, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
-
Clinical Catch-Up: April 6-10
4/13/2020
It was a very busy week for clinical trial news. Here’s a look. -
San Diego-based Arcturus Therapeutics announced it was reassuming 100 percent of its global rights for ARCT-810, a messenger RNA (mRNA) drug to treat OTC Deficiency. The drug previously had a 50/50 collaboration between Arcturus and Tubingen, Germany-based CureVac AG.
-
BioSpace Movers and Shakers: Jan. 4
1/4/2019
Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more. -
The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.
-
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.